RÉSUMÉ
Vision impairment caused by diabetic retinopathy (DR) is often irreversible, making early-stage diagnosis imperative. Raman spectroscopy emerges as a powerful tool, capable of providing molecular fingerprints of tissues. This study employs RS to detect ex vivo retinal tissue from diabetic rats at various stages of the disease. Transmission electron microscopy was utilized to reveal the ultrastructural changes in retinal tissue. Following spectral preprocessing of the acquired data, the random forest and orthogonal partial least squares-discriminant analysis algorithms were employed for spectral data analysis. The entirety of Raman spectra and all annotated bands accurately and distinctly differentiate all animal groups, and can identify significant molecules from the spectral data. Bands at 524, 1335, 543, and 435 cm-1 were found to be associated with the preproliferative phase of DR. Bands at 1045 and 1335 cm-1 were found to be associated with early stages of DR.
Sujet(s)
Rétinopathie diabétique , Apprentissage machine , Analyse spectrale Raman , Animaux , Rétinopathie diabétique/anatomopathologie , Rats , Mâle , Diabète expérimental/anatomopathologie , Diabète expérimental/induit chimiquement , Streptozocine , Rétine/anatomopathologie , Rétine/imagerie diagnostique , Rat Sprague-DawleyRÉSUMÉ
Neuroinflammation, aging, and neurodegenerative disorders are associated with excessive accumulation of neutral lipids in lipid droplets (LDs) in microglia. Type 2 diabetes mellitus (T2DM) may cause neuroinflammation and is a risk factor for neurodegenerative disorders. Here, we show that hippocampal pyramidal neurons contain smaller, more abundant LDs than their neighboring microglia. The density of LDs varied between pyramidal cells in adjacent subregions, with CA3 neurons containing more LDs than CA1 neurons. Within the CA3 region, a gradual increase in the LD content along the pyramidal layer from the hilus toward CA2 was observed. Interestingly, the high neuronal LD content correlated with less ramified microglial morphotypes. Using the db/db model of T2DM, we demonstrated that diabetes increased the number of LDs per microglial cell without affecting the neuronal LD density. High-intensity interval exercise induced smaller changes in the number of LDs in microglia but was not sufficient to counteract the diabetes-induced changes in LD accumulation. The changes observed in response to T2DM may contribute to the cerebral effects of T2DM and provide a mechanistic link between T2DM and neurodegenerative disorders.
Sujet(s)
Diabète de type 2 , Hippocampe , Gouttelettes lipidiques , Microglie , Neurones , Microglie/métabolisme , Animaux , Gouttelettes lipidiques/métabolisme , Hippocampe/métabolisme , Hippocampe/anatomopathologie , Diabète de type 2/métabolisme , Diabète de type 2/anatomopathologie , Neurones/métabolisme , Neurones/anatomopathologie , Mâle , Souris , Conditionnement physique d'animal , Cellules pyramidales/métabolisme , Cellules pyramidales/anatomopathologie , Souris de lignée C57BL , Diabète expérimental/métabolisme , Diabète expérimental/anatomopathologie , Métabolisme lipidique , Maladies neuro-inflammatoires/métabolisme , Maladies neuro-inflammatoires/anatomopathologieRÉSUMÉ
OBJECTIVES: Diabetes is closely linked to hearing loss, yet the exact mechanisms remain unclear. Cochlear stria vascularis and pericytes (PCs) are crucial for hearing. This study investigates whether high glucose induces apoptosis in the cochlear stria vascularis and pericytes via elevated ROS levels due to oxidative stress, impacting hearing loss. METHODS: We established a type II diabetes model in C57BL/6J mice and used auditory brainstem response (ABR), Evans blue staining, HE staining, immunohistochemistry, and immunofluorescence to observe changes in hearing, blood-labyrinth barrier (BLB) permeability, stria vascularis morphology, and apoptosis protein expression. Primary cultured stria vascularis pericytes were subjected to high glucose, and apoptosis levels were assessed using flow cytometry, Annexin V-FITC, Hoechst 33342 staining, Western blot, Mitosox, and JC-1 probes. RESULTS: Diabetic mice showed decreased hearing thresholds, reduced stria vascularis density, increased oxidative stress, cell apoptosis, and decreased antioxidant levels. High glucose exposure increased apoptosis and ROS content in pericytes, while mitochondrial membrane potential decreased, with AIF and cytochrome C (CytC) released from mitochondria to the cytoplasm. Adding oxidative scavengers reduced AIF and CytC release, decreasing pericyte apoptosis. DISCUSSION: Hyperglycemia may induce mitochondrial apoptosis of cochlear stria vascularis pericytes through oxidative stress.
Sujet(s)
Facteur inducteur d'apoptose , Apoptose , Cytochromes c , Hyperglycémie , Souris de lignée C57BL , Mitochondries , Stress oxydatif , Péricytes , Protéines proto-oncogènes c-bcl-2 , Espèces réactives de l'oxygène , Strie vasculaire , Animaux , Péricytes/métabolisme , Péricytes/effets des médicaments et des substances chimiques , Péricytes/anatomopathologie , Strie vasculaire/métabolisme , Strie vasculaire/anatomopathologie , Souris , Espèces réactives de l'oxygène/métabolisme , Mitochondries/métabolisme , Cytochromes c/métabolisme , Facteur inducteur d'apoptose/métabolisme , Hyperglycémie/métabolisme , Protéines proto-oncogènes c-bcl-2/métabolisme , Mâle , Diabète expérimental/métabolisme , Diabète expérimental/anatomopathologie , Cochlée/métabolisme , Cochlée/anatomopathologieRÉSUMÉ
Lipid droplets (LDs), the essential cytosolic fat storage organelles, have emerged as pivotal regulators of cellular metabolism and are implicated in various diseases. The noninvasive monitoring of LDs necessitates fluorescent probes with precise organelle selectivity and biocompatibility. Addressing this need, we have engineered a probe by strategically modifying the structure of a conventional two-photon-absorbing dipolar dye, acedan. This innovative approach induces nanoaggregate formation in aqueous environments, leading to aggregation-induced fluorescence quenching. Upon cellular uptake via clathrin-mediated endocytosis, the probe selectively illuminates within LDs through a disassembly process, effectively distinguishing LDs from the cytosol with exceptional specificity. This breakthrough enables the high-fidelity imaging of LDs in both cellular and tissue environments. In a pioneering investigation, we probed LDs in a diabetes model induced by streptozotocin, unveiling significantly heightened LD accumulation in cardiac tissues compared to other organs, as evidenced by TP imaging. Furthermore, our exploration of a lipopolysaccharide-mediated cardiomyopathy model revealed an LD accumulation during heart injury. Thus, our developed probe holds immense potential for elucidating LD-associated diseases and advancing related research endeavors.
Sujet(s)
Clathrine , Colorants fluorescents , Gouttelettes lipidiques , Animaux , Gouttelettes lipidiques/métabolisme , Gouttelettes lipidiques/composition chimique , Clathrine/métabolisme , Colorants fluorescents/composition chimique , Souris , Endocytose , Diabète expérimental/induit chimiquement , Diabète expérimental/métabolisme , Diabète expérimental/anatomopathologie , Diabète expérimental/imagerie diagnostique , Photons , Humains , Imagerie optique , Mâle , Souris de lignée C57BLRÉSUMÉ
BACKGROUND: Acute and chronic brain damage in type 2 diabetes mellitus (DM) determines the need to investigate the neuroprotective potential of glucose-lowering drugs. The purpose was to directly compare the neuroprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) with different duration of action and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in type 2 diabetic rats with and without stroke. METHODS: DM was modelled using high-fat diet and nicotinamide+streptozotocin protocol. The following groups (n = 15 each) were formed: DM without treatment, treatment with liraglutide, dulaglutide, canagliflozin as well as control group without DM and treatment. After 8 weeks, 10 rats from each group underwent middle cerebral artery occlusion. In the reperfusion period neurological deficit, neuroglial damage markers and brain necrosis were evaluated. Brain slices from the remaining 5 animals in each group were histologically examined for microglial activation and neuronal damage. RESULTS: Brain damage was similar in "DM" and "Control" (17.53 [14.23; 26.58] and 15.87 [13.40; 22.68] % of total brain volume, respectively). All study drugs diminished damage volume comparing with "DM" and "Control" whereas the necrosis volume in "DM+Liraglutide" was smaller than in "DM+Canagliflozin" and did not significantly differ from "DM+Dulaglutide" (2.9 [1.83; 4.71], 6.17 [3.88; 8.88] and 4.57 [3.27; 7.90] %). The neurological deficit was more prominent in "DM" than in "Control", while all the drugs demonstrated similar positive effect. Neurofilament light chains (NLC) did not differ between "DM" and "Control". Dulaglutide and canagliflozin caused a marked decrease in NLC. Protein S100BB level was similar in "DM" and "Control". Liraglutide caused the largest S100BB decrease, while canagliflozin did not influence it. In chronic brain ischaemia, all drugs increased the number of normal neurons, but GLP-1RAs had a more pronounced effect. DM was accompanied by increased number of activated microglial cells in Cornu Ammonis (CA)1 hippocampal region. Both GLP-1RAs reduced the number of Iba-1-positive cells, with dulaglutide being more effective than liraglutide, whereas canagliflozin did not affect this parameter. CONCLUSIONS: GLP-1RAs and SGLT-2i have neuroprotective properties against acute and chronic brain damage in diabetic rats, although the infarct-limiting effect of GLP-1RAs may be more pronounced. GLP-1RAs and SGLT-2i exert their protective effects by directly influencing neuronal survival, whereas GLP-1RAs also affect microglia.
Sujet(s)
Diabète expérimental , Diabète de type 2 , Récepteur du peptide-1 similaire au glucagon , Microglie , Inhibiteurs du cotransporteur sodium-glucose de type 2 , Animaux , Inhibiteurs du cotransporteur sodium-glucose de type 2/pharmacologie , Inhibiteurs du cotransporteur sodium-glucose de type 2/usage thérapeutique , Diabète expérimental/anatomopathologie , Diabète expérimental/complications , Diabète expérimental/métabolisme , Diabète expérimental/traitement médicamenteux , Microglie/effets des médicaments et des substances chimiques , Microglie/métabolisme , Microglie/anatomopathologie , Mâle , Récepteur du peptide-1 similaire au glucagon/agonistes , Récepteur du peptide-1 similaire au glucagon/métabolisme , Rats , Diabète de type 2/complications , Diabète de type 2/traitement médicamenteux , Diabète de type 2/métabolisme , Diabète de type 2/anatomopathologie , Rat Wistar , Souffrance cérébrale chronique/prévention et contrôle , Souffrance cérébrale chronique/étiologie , Souffrance cérébrale chronique/anatomopathologie , Liraglutide/pharmacologie , Liraglutide/usage thérapeutique , Neuroprotecteurs/pharmacologie , Neuroprotecteurs/usage thérapeutiqueRÉSUMÉ
BACKGROUND: Diabetic stress acts on the cardiac tissue to induce cardiac hypertrophy and fibrosis. Diabetes induced activated renin angiotensin system (RAS) has been reported to play a critical role in mediating cardiac hypertrophy and fibrosis. Angiotensin converting enzyme (ACE) in producing Angiotensin-II, promotes cardiomyocyte hypertrophy and fibrotic damage. ACE2, a recently discovered molecule structurally homologous to ACE, has been reported to be beneficial in reducing the effect of RAS driven pathologies. METHODS: In vivo diabetic mouse model was used and co-labelling immunostaining assay have been performed to analyse the fibrotic remodeling and involvement of associated target signaling molecules in mouse heart tissue. For in vitro analyses, qPCR and western blot experiments were performed in different groups for RNA and protein expression analyses. RESULTS: Fibrosis markers were observed to be upregulated in the diabetic mouse heart tissue as well as in high glucose treated fibroblast and cardiomyocyte cells. Hyperglycemia induced overexpression of YAP1 leads to increased expression of ß-catenin (CTNNB1) and ACE with downregulated ACE2 expression. The differential expression of ACE/ACE2 promotes TGFB1-SMAD2/3 pathway in the hyperglycemic cardiomyocyte and fibroblast resulting in increased cardiac fibrotic remodeling. CONCLUSION: In the following study, we have reported YAP1 modulates the RAS signaling pathway by inducing ACE and inhibiting ACE2 activity to augment cardiomyocyte hypertrophy and fibrosis in hyperglycemic condition. Furthermore, we have shown that hyperglycemia induced dysregulation of ACE-ACE2 activity by YAP1 promotes cardiac fibrosis through ß-catenin/TGFB1 dependent pathway.
Sujet(s)
Protéines adaptatrices de la transduction du signal , Angiotensin-converting enzyme 2 , Fibrose , Hyperglycémie , Myocytes cardiaques , Peptidyl-Dipeptidase A , Protéines de signalisation YAP , Animaux , Fibrose/métabolisme , Angiotensin-converting enzyme 2/métabolisme , Souris , Protéines de signalisation YAP/métabolisme , Peptidyl-Dipeptidase A/métabolisme , Protéines adaptatrices de la transduction du signal/métabolisme , Myocytes cardiaques/métabolisme , Myocytes cardiaques/anatomopathologie , Hyperglycémie/métabolisme , Hyperglycémie/anatomopathologie , Mâle , Facteur de croissance transformant bêta-1/métabolisme , Diabète expérimental/métabolisme , Diabète expérimental/anatomopathologie , Transduction du signal , Myocarde/métabolisme , Myocarde/anatomopathologie , Protéine Smad2/métabolisme , Souris de lignée C57BL , Cardiomégalie/métabolisme , Cardiomégalie/anatomopathologie , Protéine Smad-3/métabolisme , Système rénine-angiotensine , bêta-Caténine/métabolismeRÉSUMÉ
Diabetic nephropathy (DN) is a major healthcare challenge for individuals with diabetes and associated with increased cardiovascular morbidity and mortality. The existing rodent models do not fully represent the complex course of the human disease. Hence, developing a translational model of diabetes that reproduces both the early and the advanced characteristics of DN and faithfully recapitulates the overall human pathology is an unmet need. Here, we introduce the Nile grass rat (NGR) as a novel model of DN and characterize key pathologies underlying DN. NGRs spontaneously developed insulin resistance, reactive hyperinsulinemia, and hyperglycemia. Diabetic NGRs evolved DN and the key histopathological aspects of the human advanced DN, including glomerular hypertrophy, infiltration of mononuclear cells, tubular dilatation, and atrophy. Enlargement of the glomerular tufts and the Bowman's capsule areas accompanied the expansion of the Bowman's space. Glomerular sclerosis, renal arteriolar hyalinosis, Kimmelsteil-Wilson nodular lesions, and protein cast formations in the kidneys of diabetic NGR occurred with DN. Diabetic kidneys displayed interstitial and glomerular fibrosis, key characteristics of late human pathology as well as thickening of the glomerular basement membrane and podocyte effacement. Signs of injury included glomerular lipid accumulation, significantly more apoptotic cells, and expression of KIM-1. Diabetic NGRs became hypertensive, a known risk factor for kidney dysfunction, and showed decreased glomerular filtration rate. Diabetic NGRs recapitulate the breadth of human DN pathology and reproduce the consequences of chronic kidney disease, including injury and loss of function of the kidney. Hence, NGR represents a robust model for studying DN-related complications and provides a new foundation for more detailed mechanistic studies of the genesis of nephropathy, and the development of new therapeutic approaches.
Sujet(s)
Néphropathies diabétiques , Modèles animaux de maladie humaine , Animaux , Néphropathies diabétiques/anatomopathologie , Néphropathies diabétiques/métabolisme , Rats , Mâle , Humains , Insulinorésistance , Diabète expérimental/anatomopathologie , Diabète expérimental/métabolisme , Diabète expérimental/complications , Rein/anatomopathologie , Rein/métabolisme , Glomérule rénal/anatomopathologie , Glomérule rénal/métabolismeRÉSUMÉ
Successful treatment of diabetic wounds requires multifactorial approaches. Herein we investigated the effects of a bioengineered three-dimensional dermal derived matrix-scaffold (DMS) in combination with hyperbaric oxygen (HBO) in repairing of wound model in diabetic rats. Thirty days after induction of diabetes, a circular wound was created and treatments were performed for 21 days. Animals were randomly allocated into the untreated group, DMS group, HBO group, and DMS+HBO group. On days 7, 14, and 21, tissue samples were obtained for stereological, molecular, and tensiometrical assessments. Our results showed that the wound closure rate, volume of new dermis and epidermis, numerical density fibroblasts and blood vessels, collagen density, and biomechanical characterize were significantly higher in the treatment groups than in the untreated group, and these changes were more obvious in the DMS+HBO ones. Moreover, the expression of TGF-ß, bFGF, miRNA-21, miRNA-146a, and VEGF genes were meaningfully upregulated in treatment groups compared to the untreated group and were greater in the DMS+HBO group. This is while expression of TNF-α and IL-1ß, as well as the numerical density of neutrophil and macrophage decreased more considerably in the DMS+HBO group than in the other groups. Overall, using both DMS engraftment and HBO treatment has more effects on diabetic wound healing.
Sujet(s)
Diabète expérimental , Oxygénation hyperbare , Structures d'échafaudage tissulaires , Cicatrisation de plaie , Animaux , Diabète expérimental/thérapie , Diabète expérimental/anatomopathologie , Rats , Structures d'échafaudage tissulaires/composition chimique , Mâle , Rat Sprague-DawleyRÉSUMÉ
Diabetic muscular atrophy is becoming a fast-growing problem worldwide, including sarcopenia, which is associated with substantial mortality and morbidity risk. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been marketed and suggested to exert protective effects on not only glycemic control but also diabetic complications in diabetic patients. In this study, we investigated the therapeutic use of GLP-1RAs exendin-4, compared to antidiabetic drug metformin, for the intervention of muscular dysfunction during diabetic conditions using a streptozotocin (STZ)-induced diabetic mouse model. The results showed that both exendin-4 and metformin could effectively alleviate hyperglycemia in diabetic mice, and also counteract diabetes-induced muscle weight loss, weaker grip, and changes in muscle fiber cross-sectional area distribution. Unexpectedly, exendin-4, but not metformin, enhanced the increased kidney weight and histological change in diabetic mice. Taken together, these findings suggest that both exendin-4 and metformin could effectively improve the diabetic hyperglycemia and muscular dysfunction; but exendin-4 may aggravate the nephropathy in STZ-induced diabetic mice.
Sujet(s)
Diabète expérimental , Exénatide , Récepteur du peptide-1 similaire au glucagon , Metformine , Animaux , Exénatide/pharmacologie , Diabète expérimental/traitement médicamenteux , Diabète expérimental/complications , Diabète expérimental/anatomopathologie , Metformine/pharmacologie , Récepteur du peptide-1 similaire au glucagon/agonistes , Récepteur du peptide-1 similaire au glucagon/métabolisme , Souris , Mâle , Hypoglycémiants/pharmacologie , Streptozocine , Modèles animaux de maladie humaine , Muscles squelettiques/effets des médicaments et des substances chimiques , Muscles squelettiques/anatomopathologie , Muscles squelettiques/métabolisme , Peptides/pharmacologie , Venins/pharmacologie , Amyotrophie/traitement médicamenteux , Amyotrophie/anatomopathologie , Amyotrophie/étiologieRÉSUMÉ
Diabetic kidney disease (DKD) is often featured with redox dyshomeostatis. Pyruvate dehydrogenase kinase 4 (PDK4) is the hub for DKD development. However, the mechanism by which PDK4 mediates DKD is poorly understood. The current work aimed to elucidate the relationship between PDK4 and DKD from the perspective of redox manipulation. Oxidative stress was observed in the human proximal tubular cell line (HK-2 cells) treated with a high concentration of glucose and palmitic acid (HGL). The mechanistic study showed that PDK4 could upregulate Kelch-like ECH-associated protein 1 (Keap1) in HGL-treated HK-2 cells through the suppression of autophagy, resulting in the depletion of nuclear factor erythroid 2-related factor 2 (Nrf2), the master regulator of redox homeostasis. At the cellular level, pharmacological inhibition or genetic knockdown of PDK4 could boost Nrf2, followed by the increase of a plethora of antioxidant enzymes and ferroptosis-suppression enzymes. Meanwhile, the inhibition or knockdown of PDK4 remodeled iron metabolism, further mitigating oxidative stress and lipid peroxidation. The same trend was observed in the DKD mice model. The current work highlighted the role of PDK4 in the development of DKD and suggested that PDK4 might be a promising target for the management of DKD.
Sujet(s)
Néphropathies diabétiques , Facteur-2 apparenté à NF-E2 , Stress oxydatif , Facteur-2 apparenté à NF-E2/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques , Humains , Néphropathies diabétiques/métabolisme , Néphropathies diabétiques/anatomopathologie , Animaux , Souris , Souris de lignée C57BL , Mâle , Pyruvate dehydrogenase acetyl-transferring kinase/métabolisme , Lignée cellulaire , Protéine-1 de type kelch associée à ECH/métabolisme , Diabète expérimental/métabolisme , Diabète expérimental/complications , Diabète expérimental/anatomopathologieRÉSUMÉ
PURPOSE: In chronic hyperglycemia, the advanced glycation end product (AGE) interacts with its receptor (RAGE) and contributes to impaired wound healing by inducing oxidative stress, generating dysfunctional macrophages, and prolonging the inflammatory response. Additionally, uncontrolled levels of proteases, including metallomatrix protease-9 (MMP-9), in the diabetic wound bed degrade the extracellular matrix (ECM) and biological cues that augment healing. A multifunctional antimicrobial hydrogel (Immuno-gel) containing RAGE and MMP-9 inhibitors can regulate the wound microenvironment and promote scar-free healing. RESULTS: Immuno-gel was characterized and the wound healing efficacy was determined in vitro cell culture and in vivo diabetic Wistar rat wound model using ELISA, Western blot, and Immunofluorescence staining. The Immuno-gel exhibited a highly porous morphology with excellent in vitro cytocompatibility. AGE-stimulated macrophages treated with the Immuno-gel released higher levels of pro-healing cytokines in vitro. In the hydrogel-wound interface of diabetic Wistar rats, Immuno-gel treatment significantly reduced MMP-9 and NF-κB expression and enhanced pro-healing (M2) macrophage population and pro-healing cytokines. CONCLUSION: Altogether, this study suggests that Immuno-gel simultaneously attenuates macrophage dysfunction through the inhibition of AGE/RAGE signaling and reduces MMP-9 overexpression, both of which favor scar-free healing. The combinatorial treatment with RAGE and MMP-9 inhibitors via Immuno-gel simultaneously modulates the diabetic wound microenvironment, making it a promising novel treatment to accelerate diabetic wound healing.
Sujet(s)
Diabète expérimental , Produits terminaux de glycation avancée , Hydrogels , Matrix metalloproteinase 9 , Rat Wistar , Récepteur spécifique des produits finaux de glycosylation avancée , Transduction du signal , Cicatrisation de plaie , Animaux , Matrix metalloproteinase 9/métabolisme , Produits terminaux de glycation avancée/métabolisme , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Hydrogels/pharmacologie , Récepteur spécifique des produits finaux de glycosylation avancée/métabolisme , Diabète expérimental/métabolisme , Diabète expérimental/anatomopathologie , Rats , Transduction du signal/effets des médicaments et des substances chimiques , Macrophages/effets des médicaments et des substances chimiques , Macrophages/métabolisme , Macrophages/immunologie , Mâle , SourisRÉSUMÉ
Cytokine-induced ß-cell apoptosis is a major pathogenic mechanism in type 1 diabetes (T1D). Despite significant advances in understanding its underlying mechanisms, few drugs have been translated to protect ß-cells in T1D. Epigenetic modulators such as bromodomain-containing BET (bromo- and extra-terminal) proteins are important regulators of immune responses. Pre-clinical studies have demonstrated a protective effect of BET inhibitors in an NOD (non-obese diabetes) mouse model of T1D. However, the effect of BET protein inhibition on ß-cell function in response to cytokines is unknown. Here, we demonstrate that I-BET, a BET protein inhibitor, protected ß-cells from cytokine-induced dysfunction and death. In vivo administration of I-BET to mice exposed to low-dose STZ (streptozotocin), a model of T1D, significantly reduced ß-cell apoptosis, suggesting a cytoprotective function. Mechanistically, I-BET treatment inhibited cytokine-induced NF-kB signaling and enhanced FOXO1-mediated anti-oxidant response in ß-cells. RNA-Seq analysis revealed that I-BET treatment also suppressed pathways involved in apoptosis while maintaining the expression of genes critical for ß-cell function, such as Pdx1 and Ins1. Taken together, this study demonstrates that I-BET is effective in protecting ß-cells from cytokine-induced dysfunction and apoptosis, and targeting BET proteins could have potential therapeutic value in preserving ß-cell functional mass in T1D.
Sujet(s)
Apoptose , Cytokines , Cellules à insuline , Facteur de transcription NF-kappa B , Transduction du signal , Animaux , Cellules à insuline/effets des médicaments et des substances chimiques , Cellules à insuline/métabolisme , Cellules à insuline/anatomopathologie , Facteur de transcription NF-kappa B/métabolisme , Souris , Cytokines/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Apoptose/effets des médicaments et des substances chimiques , Diabète expérimental/anatomopathologie , Diabète expérimental/métabolisme , Diabète de type 1/métabolisme , Diabète de type 1/anatomopathologie , Protéine O1 à motif en tête de fourche/métabolisme , Souris de lignée NOD , Mâle , Souris de lignée C57BLRÉSUMÉ
BACKGROUND: Patients with diabetes are prone to acute kidney injury (AKI) with a high mortality rate, poor prognosis, and a higher risk of progression to chronic kidney disease than non-diabetic patients. METHODS: Streptozotocin (STZ)-treated type 1 and db/db type 2 diabetes model were established, AKI model was induced in mice by ischemia-reperfusion injury(IRI). Mouse proximal tubular cell cells were subjected to high glucose and hypoxia-reoxygenation in vitro. Transcriptional RNA sequencing was performed for clustering analysis and target gene screening. Renal structural damage was determined by histological staining, whereas creatinine and urea nitrogen levels were used to measure renal function. RESULTS: Deteriorated renal function and renal tissue damage were observed in AKI mice with diabetic background. RNA sequencing showed a decrease in fatty acid oxidation (FAO) pathway and an increase in abnormal glycolysis. Treatment with Dapa, Sitagliptin(a DPP-4 inhibitor)and insulin reduced blood glucose levels in mice, and improved renal function. However, Dapa had a superior therapeutic effect and alleviated aberrant FAO and glycosis. Dapa reduced cellular death in cultured cells under high glucose hypoxia-reoxygenation conditions, alleviated FAO dysfunction, and reduced abnormal glycolysis. RNA sequencing showed that SIRT3 expression was reduced in diabetic IRI, which was largely restored by Dapa intervention. 3-TYP, a SIRT3 inhibitor, reversed the renal protective effects of Dapa and mediated abnormal FAO and glycolysis in mice and tubular cells. CONCLUSION: Our study provides experimental evidence for the use of Dapa as a means to reduce diabetic AKI by ameliorating metabolic reprogramming in renal tubular cells.
Sujet(s)
Atteinte rénale aigüe , Composés benzhydryliques , Diabète de type 2 , Néphropathies diabétiques , Glucosides , , Insuffisance rénale chronique , Animaux , Mâle , Souris , Atteinte rénale aigüe/métabolisme , Atteinte rénale aigüe/traitement médicamenteux , Atteinte rénale aigüe/anatomopathologie , Atteinte rénale aigüe/étiologie , Diabète expérimental/complications , Diabète expérimental/métabolisme , Diabète expérimental/traitement médicamenteux , Diabète expérimental/anatomopathologie , Diabète de type 2/complications , Diabète de type 2/métabolisme , Diabète de type 2/traitement médicamenteux , Diabète de type 2/anatomopathologie , Néphropathies diabétiques/métabolisme , Néphropathies diabétiques/traitement médicamenteux , Néphropathies diabétiques/anatomopathologie , Glucosides/pharmacologie , Glucosides/usage thérapeutique , /effets des médicaments et des substances chimiques , Souris de lignée C57BL , Coactivateur 1-alpha du récepteur gamma activé par les proliférateurs de peroxysomes/métabolisme , Coactivateur 1-alpha du récepteur gamma activé par les proliférateurs de peroxysomes/génétique , Insuffisance rénale chronique/métabolisme , Insuffisance rénale chronique/traitement médicamenteux , Insuffisance rénale chronique/anatomopathologie , Transduction du signal/effets des médicaments et des substances chimiques , Sirtuine-3/métabolisme , Sirtuine-3/génétique , Composés benzhydryliques/pharmacologie , Composés benzhydryliques/usage thérapeutiqueRÉSUMÉ
Diabetic peripheral neuropathy (DPN) is a common complication associated with diabetes, and can affect quality of life considerably. Dorsal root ganglion (DRG) plays an important role in the development of DPN. However, the relationship between DRG and the pathogenesis of DPN still lacks a thorough exploration. Besides, a more in-depth understanding of the cell type composition of DRG, and the roles of different cell types in mediating DPN are needed. Here we conducted single-cell RNA-seq (scRNA-seq) for DRG tissues isolated from healthy control and DPN rats. Our results demonstrated DRG includes eight cell-type populations (e.g., neurons, satellite glial cells (SGCs), Schwann cells (SCs), endothelial cells, fibroblasts). In the heterogeneity analyses of cells, six neuron sub-types, three SGC sub-types and three SC sub-types were identified, additionally, biological functions related to cell sub-types were further revealed. Cell communication analysis showed dynamic interactions between neurons, SGCs and SCs. We also found that the aberrantly expressed transcripts in sub-types of neurons, SGCs and SCs with DPN were associated with diabetic neuropathic pain, cell apoptosis, oxidative stress, etc. In conclusion, this study provides a systematic perspective of the cellular composition and interactions of DRG tissues, and suggests that neurons, SGCs and SCs play vital roles in the progression of DPN. Our data may provide a valuable resource for future studies regarding the pathophysiological effect of particular cell type in DPN.
Sujet(s)
Neuropathies diabétiques , Ganglions sensitifs des nerfs spinaux , Analyse de profil d'expression de gènes , Cellules de Schwann , Analyse sur cellule unique , Animaux , Ganglions sensitifs des nerfs spinaux/métabolisme , Ganglions sensitifs des nerfs spinaux/anatomopathologie , Neuropathies diabétiques/anatomopathologie , Neuropathies diabétiques/génétique , Neuropathies diabétiques/métabolisme , Rats , Cellules de Schwann/métabolisme , Cellules de Schwann/anatomopathologie , Mâle , Transcriptome , Neurones/métabolisme , Neurones/anatomopathologie , Rat Sprague-Dawley , Diabète expérimental/génétique , Diabète expérimental/anatomopathologie , Analyse de l'expression du gène de la cellule uniqueRÉSUMÉ
Autoreactivity of the complement system may escalate the development of diabetic nephropathy. We used the BTBR OB mouse model of type 2 diabetes to investigate the role of the complement factor mannan-binding lectin (MBL) in diabetic nephropathy. Female BTBR OB mice (n = 30) and BTBR non-diabetic WT mice (n = 30) were included. Plasma samples (weeks 12 and 21) and urine samples (week 19) were analyzed for MBL, C3, C3-fragments, SAA3, and markers for renal function. Renal tissue sections were analyzed for fibrosis, inflammation, and complement deposition. The renal cortex was analyzed for gene expression (complement, inflammation, and fibrosis), and isolated glomerular cells were investigated for MBL protein. Human vascular endothelial cells cultured under normo- and hyperglycemic conditions were analyzed by flow cytometry. We found that the OB mice had elevated plasma and urine concentrations of MBL-C (p < 0.0001 and p < 0.001, respectively) and higher plasma C3 levels (p < 0.001) compared to WT mice. Renal cryosections from OB mice showed increased MBL-C and C4 deposition in the glomeruli and increased macrophage infiltration (p = 0.002). Isolated glomeruli revealed significantly higher MBL protein levels (p < 0.001) compared to the OB and WT mice, and no renal MBL expression was detected. We report that chronic inflammation plays an important role in the development of DN through the binding of MBL to hyperglycemia-exposed renal cells.
Sujet(s)
Diabète de type 2 , Néphropathies diabétiques , Modèles animaux de maladie humaine , Inflammation , Lectine liant le mannose , Animaux , Lectine liant le mannose/métabolisme , Lectine liant le mannose/génétique , Lectine liant le mannose/sang , Souris , Diabète de type 2/métabolisme , Diabète de type 2/anatomopathologie , Néphropathies diabétiques/métabolisme , Néphropathies diabétiques/anatomopathologie , Inflammation/métabolisme , Inflammation/anatomopathologie , Femelle , Humains , Rein/métabolisme , Rein/anatomopathologie , Diabète expérimental/métabolisme , Diabète expérimental/anatomopathologieRÉSUMÉ
The incidence of cardiovascular disorders is continuously rising, and there are no effective drugs to treat diabetes-associated heart failure. Thus, there is an urgent need to explore alternate approaches, including natural plant extracts, which have been successfully exploited for therapeutic purposes. The current study aimed to explore the cardioprotective potential of Phoenix dactylifera (PD) extract in experimental diabetic cardiomyopathy (DCM). Following in vitro phytochemical analyses, Wistar albino rats (N = 16, male; age 2-3 weeks) were fed with a high-fat or standard diet prior to injection of streptozotocin (35 mg/kg i.p.) after 2 months and separation into the following four treatment groups: healthy control, DCM control, DCM metformin (200 mg/kg/day, as the reference control), and DCM PD treatment (5 mg/kg/day). After 25 days, glucolipid and myocardial blood and serum markers were assessed along with histopathology and gene expression of both heart and pancreatic tissues. The PD treatment improved glucolipid balance (FBG 110 ± 5.5 mg/dL; insulin 17 ± 3.4 ng/mL; total cholesterol 75 ± 8.5 mg/dL) and oxidative stress (TOS 50 ± 7.8 H2O2equiv./L) in the DCM rats, which was associated with preserved structural integrity of both the pancreas and heart compared to the DCM control (FBG 301 ± 10 mg/dL; insulin 27 ± 3.4 ng/mL; total cholesterol 126 ± 10 mg/dL; TOS 165 ± 12 H2O2equiv./L). Gene expression analyses revealed that PD treatment upregulated the expression of insulin signaling genes in pancreatic tissue (INS-I 1.69 ± 0.02; INS-II 1.3 ± 0.02) and downregulated profibrotic gene expression in ventricular tissue (TGF-ß 1.49 ± 0.04) compared to the DCM control (INS-I 0.6 ± 0.02; INS-II 0.49 ± 0.03; TGF-ß 5.7 ± 0.34). Taken together, these data indicate that Phoenix dactylifera may offer cardioprotection in DCM by regulating glucolipid balance and metabolic signaling.
Sujet(s)
Diabète expérimental , Cardiomyopathies diabétiques , Métabolisme lipidique , Phoeniceae , Extraits de plantes , Rat Wistar , Animaux , Phoeniceae/composition chimique , Extraits de plantes/pharmacologie , Extraits de plantes/usage thérapeutique , Mâle , Cardiomyopathies diabétiques/métabolisme , Cardiomyopathies diabétiques/traitement médicamenteux , Cardiomyopathies diabétiques/anatomopathologie , Cardiomyopathies diabétiques/prévention et contrôle , Rats , Métabolisme lipidique/effets des médicaments et des substances chimiques , Diabète expérimental/traitement médicamenteux , Diabète expérimental/métabolisme , Diabète expérimental/complications , Diabète expérimental/anatomopathologie , Méthanol/composition chimique , Stress oxydatif/effets des médicaments et des substances chimiques , Remodelage ventriculaire/effets des médicaments et des substances chimiques , Cardiotoniques/pharmacologie , Cardiotoniques/usage thérapeutique , Myocarde/métabolisme , Myocarde/anatomopathologieRÉSUMÉ
BACKGROUND: Diabetes mellitus commonly causes endothelial cell and smooth muscle cell death in penile cavernous tissue. AIM: The study sought to study the mode of cell death in the penile cavernous tissue in type 1 diabetic rats. METHODS: A total of 36 Sprague Dawley rats 10 weeks of age were randomly divided into 2 groups: a normoglycemic group and type 1 diabetic group (intraperitoneal injection of Streptozotocin (STZ), 60 mg/kg). We randomly selected 6 rats from each group for tests at the end of 11, 14, and 18 weeks of age, respectively. All rats were able to eat and drink freely. The ratio of maximum intracavernous pressure to mean arterial pressure, concentration of serum testosterone, level of nitric oxide in the penile cavernosum, and expression of active caspase-1 (pyroptosis) and active caspase-3 (apoptosis) were determined. OUTCOMES: At the end of weeks 4 and 8 of type 1 diabetes, the proportions of endothelial cells and smooth muscle cells undergoing apoptosis and pyroptosis in penile cavernous tissue are different. RESULTS: The ratio of maximum intracavernous pressure to mean arterial pressure and nitric oxide levels were significantly lower in the 4- and 8-week diabetic groups than in the normoglycemic group (P < .01). Penile endothelial cell pyroptosis (5.67 ± 0.81%), smooth muscle cell apoptosis (23.72 ± 0.48%), total cell pyroptosis (9.67 ± 0.73%), and total apoptosis (10.52 ± 1.45%) were significantly greater in the 4-week diabetic group than in the normoglycemic group (P < .01). The proportion of endothelial cell pyroptosis (24.4 ± 3.69%), endothelial cell apoptosis (22.13 ± 2.43%), total cell pyroptosis (14.75 ± 0.93%), and total apoptosis (14.82 ± 1.08%) in the penile tissues of the 8-week diabetic group were significantly greater than those in the normoglycemic group (P < .01).The 8-week survival proportions of diabetic endothelial cells (38.86 ± 8.85%) and smooth muscle cells (44.46 ± 2.94%) was significantly lower than the 4-week survival proportions of endothelial cells (93.17 ± 8.07%) and smooth muscle cells (75.12 ± 4.76%) (P < .05). CLINICAL TRANSLATION: Inhibition of cell death by different methods at different stages may be the key to the treatment of type 1 diabetes-induced erectile dysfunction. STRENGTHS AND LIMITATIONS: The effect of type 1 diabetes on other types of cell death in penile cavernous tissue needs further study. CONCLUSION: The mode of death of endothelial cells in the cavernous tissue of the penis in the early stage in diabetic rats is dominated by pyroptosis, and the death of smooth muscle cells is dominated by apoptosis. Endothelial cell and smooth muscle cell death are not consistent at different stages of diabetes progression.
Sujet(s)
Apoptose , Caspase-3 , Diabète expérimental , Diabète de type 1 , Monoxyde d'azote , Pénis , Rat Sprague-Dawley , Mâle , Animaux , Pénis/anatomopathologie , Diabète expérimental/physiopathologie , Diabète expérimental/anatomopathologie , Diabète expérimental/complications , Rats , Diabète de type 1/physiopathologie , Diabète de type 1/complications , Diabète de type 1/anatomopathologie , Caspase-3/métabolisme , Apoptose/physiologie , Monoxyde d'azote/métabolisme , Pyroptose/physiologie , Testostérone/sang , Caspase-1/métabolisme , Cellules endothéliales/anatomopathologie , Mort cellulaireRÉSUMÉ
Diabetic peripheral neuropathy (DPN) is caused by several factors, including reactive free oxygen radicals (ROS)-induced excessive Ca2+ influx. Transient receptor potential (TRP) vanilloid 4 (TRPV4) is a member of the Ca2+-permeable TRP superfamily. Resveratrol (RESV) has been extensively utilized in TRP channel regulation due to its pharmacological properties, which include antioxidant and TRP inhibitory effects. The protective function of RESV and the contribution of TRPV4 to streptozotocin (STZ)-induced neuropathic pain in mice are still unclear. Here, we evaluated the effects of RESV through the modulation of TRPV4 on Ca2+ influx, ROS-mediated pain, apoptosis, and oxidative damage in the mouse dorsal root ganglion (DRGs). From the 32 mice, four groups were induced: control, RESV, STZ, and STZ + RESV. We found that the injection of RESV reduced the changes caused by the STZ-induced stimulation of TRPV4, which in turn increased mechanical/thermal neuropathic pain, cytosolic Ca2+ influx, TRPV4 current density, oxidants (lipid peroxidation, mitochondrial ROS, and cytosolic ROS), and apoptotic markers (caspase-3, -8, and -9). The RESV injection also increased the STZ-mediated reduction of viability of DRG and the amounts of glutathione, glutathione peroxidase, vitamin A, ß-carotene, and vitamin E in the brain, erythrocytes, plasma, liver, and kidney. All of these findings suggest that TRPV4 stimulation generates oxidative neurotoxicity, neuropathic pain, and apoptosis in the STZ-induced diabetic mice. On the other hand, neurotoxicity and apoptosis were reduced due to the downregulation of TRPV4 carried out through the RESV injection.
Sujet(s)
Apoptose , Diabète expérimental , Ganglions sensitifs des nerfs spinaux , Névralgie , Stress oxydatif , Resvératrol , Canaux cationiques TRPV , Animaux , Canaux cationiques TRPV/métabolisme , Apoptose/effets des médicaments et des substances chimiques , Resvératrol/pharmacologie , Resvératrol/usage thérapeutique , Mâle , Diabète expérimental/complications , Diabète expérimental/traitement médicamenteux , Diabète expérimental/métabolisme , Diabète expérimental/anatomopathologie , Stress oxydatif/effets des médicaments et des substances chimiques , Névralgie/traitement médicamenteux , Névralgie/métabolisme , Névralgie/anatomopathologie , Ganglions sensitifs des nerfs spinaux/métabolisme , Ganglions sensitifs des nerfs spinaux/effets des médicaments et des substances chimiques , Ganglions sensitifs des nerfs spinaux/anatomopathologie , Souris , Calcium/métabolisme , Espèces réactives de l'oxygène/métabolisme , Streptozocine/toxicité , Neuropathies diabétiques/métabolisme , Neuropathies diabétiques/traitement médicamenteux , Neuropathies diabétiques/anatomopathologieRÉSUMÉ
The poor healing characteristics of diabetic foot ulcers are partially attributed to diabetes-induced pro-inflammatory wounds. Our previous study reported that both miR-146a-5p and miR-200b-3p decrease endothelial inflammation in human aortic endothelial cells and db/db diabetic mice. Although miR-146a-5p has been reported to improve diabetic wound healing, the role of miR-200b-3p is not clear. This study compared the roles of these miRNAs in diabetic wound healing. Two 8-mm full-thickness wounds were created in 12-week-old male db/db mice on the left and right back. After surgery, 100 ng miR-146a-5p, miR-200b-3p, or miR-negative control (NC) was injected in each wound. Full-thickness skin samples were harvested from mice at the 14th day for real-time polymerase chain reaction and immunohistochemistry analyses. At the 14th day, the miR-200b-3p group showed better wound healing and greater granulation tissue thickness than the miR-146a-5p group. The miR-200b-3p group showed a significant decrease of IL-6 and IL-1ß gene expression and a significant increase of Col3α1 gene expression compared to those in the miR-NC group. The miR-200b-3p group had the lowest gene expression of TGF-ß1, followed by the miR-146a-5p and miR-NC groups. Our findings suggest that the miR-200b-3p group had better healing characteristics than the other two groups. Immunohistochemical staining revealed that CD68 immunoreactivity was significantly decreased in both the miR-146a-5p and miR-200b-3p groups compared with that in the miR-NC group. In addition, CD31 immunoreactivity was significantly higher in the miR-200b-3p group than in the miR-146a-5p group. In conclusion, these results suggest that miR-200b-3p is more effective than miR-146a-5p in promoting diabetic wound healing through its anti-inflammatory and pro-angiogenic effects.
Sujet(s)
microARN , Cicatrisation de plaie , microARN/génétique , microARN/métabolisme , Animaux , Cicatrisation de plaie/génétique , Mâle , Souris , Facteur de croissance transformant bêta-1/métabolisme , Facteur de croissance transformant bêta-1/génétique , Pied diabétique/génétique , Pied diabétique/métabolisme , Pied diabétique/anatomopathologie , Néovascularisation physiologique/génétique , Interleukine-6/métabolisme , Interleukine-6/génétique , Antigènes de différenciation des myélomonocytes/métabolisme , Antigènes de différenciation des myélomonocytes/génétique , Interleukine-1 bêta/métabolisme , Interleukine-1 bêta/génétique , Diabète expérimental/complications , Diabète expérimental/génétique , Diabète expérimental/métabolisme , Diabète expérimental/anatomopathologie , Antigènes CD/génétique , Antigènes CD/métabolisme , Peau/métabolisme , Peau/anatomopathologie , Inflammation/génétique , Inflammation/anatomopathologie , Inflammation/métabolisme , Souris de lignée C57BL ,RÉSUMÉ
Dihydromyricetin (DHM) is a flavonoid from vine tea with broad pharmacological benefits, which improve inflammation by blocking the NF-κB pathway. A growing body of research indicates that chronic kidney inflammation is vital to the pathogenesis of diabetic renal fibrosis. Sphingosine kinase-1 (SphK1) is a key regulator of diabetic renal inflammation, which triggers the NF-κB pathway. Hence, we evaluated whether DHM regulates diabetic renal inflammatory fibrosis by acting on SphK1. Here, we demonstrated that DHM effectively suppressed the synthesis of fibrotic and inflammatory adhesion factors like ICAM-1, and VCAM-1 in streptozotocin-treated high-fat diet-induced diabetic mice and HG-induced glomerular mesangial cells (GMCs). Moreover, DHM significantly suppressed NF-κB pathway activation and reduced SphK1 activity and protein expression under diabetic conditions. Mechanistically, the results of molecular docking, molecular dynamics simulation, and cellular thermal shift assay revealed that DHM stably bound to the binding pocket of SphK1, thereby reducing sphingosine-1-phosphate content and SphK1 enzymatic activity, which ultimately inhibited NF-κB DNA binding, transcriptional activity, and nuclear translocation. In conclusion, our data suggested that DHM inhibited SphK1 phosphorylation to prevent NF-κB activation thus ameliorating diabetic renal fibrosis. This supported the clinical use and further drug development of DHM as a potential candidate for treating diabetic renal fibrosis.